<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00036296</url>
  </required_header>
  <id_info>
    <org_study_id>IXL-202-18-189</org_study_id>
    <nct_id>NCT00036296</nct_id>
  </id_info>
  <brief_title>Effects of Talampanel on Patients With Advanced Parkinson's Disease</brief_title>
  <official_title>Effects of Talampanel on Patients With Advanced Parkinson's Disease Who Have Been on Sinemet for More Than 5 Years and Have Dyskinesia (Abnormal Involuntary Movements)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Branded Pharmaceutical Products R&amp;D, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Branded Pharmaceutical Products R&amp;D, Inc.</source>
  <brief_summary>
    <textblock>
      The purpose of this research study is to test the safety and effectiveness of the study drug,&#xD;
      Talampanel, when used to treat patients with involuntary movements known as dyskinesias, as a&#xD;
      result of treatment to Parkinson's disease.&#xD;
&#xD;
      It is not clear why people with Parkinson's disease develop involuntary movements&#xD;
      (dyskinesias) but studies show that blocking receptors in the brain for a chemical called&#xD;
      glutamate decreases these movements. Talampanel is a drug which blocks these receptors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">February 2007</completion_date>
  <primary_completion_date type="Actual">February 2007</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Dyskinesias</condition>
  <condition>Parkinson Disease</condition>
  <condition>Movement Disorders</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>75mg per day (in 3 doses) Talampanel for 22 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>3 doses a day for 22 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>talampanel</intervention_name>
    <description>75mg per day divided into 3 doses for 22 days</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Troublesome on-period dyskinesias as defined by a Unified Parkinson's Disease Rating&#xD;
             Scale (UPDRS) dyskinesia sub-score &gt;25% of Duration of dyskinesia during waking hours&#xD;
             and 33 must have moderate disability&#xD;
&#xD;
          -  Lang-Fahn dyskinesia rating score more than 2 for at least two of the 5 tasks&#xD;
&#xD;
          -  Must have Dyskinesia on average 25% of waking hours/day based on Patient Diaries&#xD;
&#xD;
          -  Have been diagnosed with Parkinson's disease &gt; 5 years at Screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous surgical therapies for PD&#xD;
&#xD;
          -  Isolated or predominantly diphasic dyskinesias&#xD;
&#xD;
          -  Moderate Dementia&#xD;
&#xD;
          -  On disallowed concomitant medications including CYP3A4 inhibitors and inducers,&#xD;
             amantadine, etc.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Canada</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>October 2009</verification_date>
  <study_first_submitted>May 8, 2002</study_first_submitted>
  <study_first_submitted_qc>May 8, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2002</study_first_posted>
  <last_update_submitted>April 11, 2011</last_update_submitted>
  <last_update_submitted_qc>April 11, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 13, 2011</last_update_posted>
  <responsible_party>
    <name_title>Rivka Kreitman, Ph.D., Vice President, Innovative Research and Development</name_title>
    <organization>Teva Neuroscience</organization>
  </responsible_party>
  <keyword>Involuntary Movements</keyword>
  <keyword>Abnormal Movements</keyword>
  <keyword>Advanced Parkinson's disease</keyword>
  <keyword>Levodopa induced dyskinesia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Dyskinesias</mesh_term>
    <mesh_term>Movement Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

